GLG News by Oncologists in Private Practice in the U.S.

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

The positive interim results released by Novelos Therapeutics about its chemoprotectant / chemopotentiator NOV-002 were not very meaty: Divining the true implications of pathologic CRs in neo-adjuvant breast cancer can be tricky.  Plus, this was a open label, phase II study, and the number of patients reported...

Now that liquid Leukine (GM-CSF) has been withdrawn by Bayer, Amgen commands the North American G-CSF market with its Neupogen and Neulasta.  However, Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL) has been treating patients with a biosimilar G-CSF called Neukine since 2004.  And...

The data from this phase Ib study will allow Proteolix to proceed with a phase II study of their novel proteasome inhibitor Carfilzomib in patients with advanced solid tumors.  Phase II studies are already underway investigating its activity in myeloma, the tumor type shown to be sensitive...

This large study did not show any benefit for Rituxan in a general lupus population. But, patients with nephritis - a common kidney complication - were specifically excluded from this study and are specifically being studied with Rituxan in the LUNAR study, which will yield results in early...

This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have...

While only a Phase II study, it suggest that Oral PBI-14 may be of significant help to cancer patients who suffer from anemia caused by their chemotherapy. http://www.pipelinereview.com/content/view/19152/109/ This is especially notable given the recent saftey concerns about and decline in use...

New data with low and high dose of Avastin with Taxoter

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...

Sirolimus has shown activity in shrinking benign tumors associated with tuberous sclerosis......opens the door for further exploration alone and combo in other mTOR driven disorders